Latest California Healthline Stories
Doctors Abandon a Diagnosis Used to Justify Police Custody Deaths. It Might Live On, Anyway.
The American College of Emergency Physicians agreed to withdraw its 2009 white paper on excited delirium, removing the only official medical pillar of support left for the theory that has played a key role in absolving police of culpability for in-custody deaths.
California prohíbe el controversial diagnóstico de “delirio excitado”
El gobernador demócrata Gavin Newsom firmó un proyecto de ley el 8 de octubre para prohibir que los forenses, doctores, y examinadores médicos incluyeran el síndrome de “delirio excitado” en certificados de defunción o informes de autopsias.
California Bans Controversial ‘Excited Delirium’ Diagnosis
California is the first state to ban the controversial diagnosis known as “excited delirium,” which has been used increasingly to justify excessive force by law enforcement. A human rights advocate described the law, signed this week by Gov. Gavin Newsom, as a “watershed moment” in criminal justice.
Thousands Got Exactech Knee or Hip Replacements. Then, Patients Say, the Parts Began to Fail.
In a torrent of lawsuits, patients accuse Florida device maker Exactech of hiding knee and hip implant defects for years. The company denies the allegations.
Police Blame Some Deaths on ‘Excited Delirium.’ ER Docs Consider Pulling Plug on Term.
The American College of Emergency Physicians will vote in early October on whether to disavow its 2009 research paper on excited delirium, which has been cited as a cause of death and used as a legal defense by police officers in several high-profile cases.
KFF Health News' 'What the Health?': More Medicaid Messiness
At least 30 states are reinstating coverage for children wrongly removed from the rolls under Medicaid redetermination, the federal government reported. It’s just the latest hiccup in the massive effort to review the eligibility of Medicaid beneficiaries now that the program’s pandemic-era expansion has expired. And federal oversight of the so-called unwinding would be further complicated by an impending government shutdown. Rachel Roubein of The Washington Post, Sandhya Raman of CQ Roll Call, and Sarah Karlin-Smith of Pink Sheet join KFF Health News chief Washington correspondent Julie Rovner to discuss these issues and more. Also this week, Rovner interviews KFF Health News’ Samantha Liss, who reported and wrote the latest KFF Health News-NPR “Bill of the Month” feature, about a hospital bill that followed a deceased patient’s family for more than a year.
A Decades-Long Drop in Teen Births Is Slowing, and Advocates Worry a Reversal Is Coming
After three decades of declines in teen pregnancies, data shows the rates are starting to plateau. The reversal of “Roe v. Wade,” coupled with efforts to suspend sex education in schools and higher rates of youth mental health issues post-pandemic, could culminate in a perfect storm.
State Officials Seek ‘CARE’ Without Coercion as New Mental Health Courts Launch This Fall
In Orange County, California, officials are threading a delicate needle. They want to persuade people with psychosis to accept treatment without coercion as the state’s new CARE Courts roll out in October.
KFF Health News' 'What the Health?': A Not-So-Health-y GOP Debate
The first Republican presidential debate of the 2024 cycle took place without front-runner Donald Trump — and with hardly a mention of health issues save for abortion. Meanwhile, in Florida, patients dropped from the Medicaid program are suing the state for not giving them enough notice or a way to contest their being dropped from the program. Margot Sanger-Katz of The New York Times, Joanne Kenen of the Johns Hopkins Bloomberg School of Public Health and Politico, and Victoria Knight of Axios join KFF Health News’ Julie Rovner to discuss these issues and more. Plus, for “extra credit,” the panelists suggest health policy stories they read this week they think you should read, too.
KFF Health News' 'What the Health?': Abortion Pill’s Legal Limbo Continues
A federal appeals court issued a split decision on whether the abortion pill mifepristone should remain on the market — rejecting a lower court’s decision to effectively cancel the drug’s FDA approval in 2000, while ordering the rollback of more recent rules that made the drug easier to obtain. Nothing changes immediately, however, as the Supreme Court blocked the lower court’s ruling in the spring. It will be up to the high court to determine whether the pill remains available in the U.S. and under which conditions. Sarah Karlin-Smith of the Pink Sheet, Alice Miranda Ollstein of Politico, and Shefali Luthra of The 19th join KFF Health News’ chief Washington correspondent, Julie Rovner, to discuss these issues and more. Plus, for “extra credit,” the panelists suggest health policy stories they read this week they think you should read, too.